Ian D. Davis, MBBS, PhD, and Christopher Sweeney, MBBS, on Prostate Cancer: ENZAMET Trial on Enzalutamide for Metastatic Hormone-Sensitive Disease
2019 ASCO Annual Meeting
Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss phase III findings from their international trial on adding enzalutamide as a new treatment option with testosterone suppression for metastatic hormone-sensitive prostate cancer (Abstract LBA2).
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, offers commentary on phase III findings from the RELAY study, which showed that erlotinib plus ramucirumab led to superior progression-free survival in previously untreated patients with EGFR mutant–positive NSCLC (Abstract 9000).
Thomas J. George, MD, of NRG Oncology and The University of Florida Health Cancer Center, discusses the initial phase II results from a clinical trial using total neoadjuvant therapy (including veliparib and chemoradiation treatment) for locally advanced rectal cancer (Abstract 3505).
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses the first study of ribociclib plus endocrine therapy vs endocrine therapy alone to demonstrate significantly longer overall survival in peri- and premenopausal women with advanced breast cancer (Abstract LBA1008).
Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings that showed, for adults with locally advanced cancer across five different disease sites, proton chemoradiotherapy was associated with significantly reduced acute adverse events, with no difference in disease-free or overall survival (Abstract 6521).
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, University of Paris-Sud, discusses study findings showing that not only does darolutamide prolong metastasis-free survival, it maintains quality of life as well as delays worsening of pain and disease-related symptoms compared with placebo for patients with nonmetastatic castrate-resistant prostate cancer (Abstract 5000).
